144-week data from gilead's study 934 comparing viread® and emtriva®to combivir®both in combination with sustiva(r) published in journal of acquired immune deficiency syndrome
JANSSEN ANNOUNCES WORLDWIDE AGREEMENT TO DEVELOP AND COMMERCIALIZE
JAK INHIBITOR FOR IMMUNOLOGICAL DISEASES
-- Orally Administered Investigational Therapy Expands Global Immunology Portfolio --
Horsham, PA, October 1, 2012 –
Janssen Biotech, Inc. (“Janssen”) announced today that it has entered
into a license agreement with Astellas Pharma Inc. (“Astellas”) for the worldwide development and
commercialization, except in Japan, of ASP015K, an oral, small molecule Janus Kinase (JAK) inhibitor.
ASP015K is currently in Phase 2b development as a once-daily oral treatment for moderate-to-severe
rheumatoid arthritis (RA), following a successful Phase 2a study demonstrating its potential in the
treatment of moderate-to-severe plaque psoriasis. Rheumatoid arthritis affects between one and two
percent of the world’s population and results in pain and inflammation, and in some cases, joint
destruction and disability. Psoriasis, a chronic inflammatory disease that results from the overproduction
of skin cells, affects 125 million people worldwide and can range from mild to severe and disabling.
“Janssen has a heritage of innovation and delivering transformative medicines to address unmet needs in
immunologic diseases,” said Susan Dillon, Ph.D., Global Therapeutic Area Head, Immunology, Janssen
Research & Development, LLC. “We are committed to expanding the portfolio of new treatments for
patients with serious immune-mediated diseases and are excited to add Astellas’ ASP015K to our
Under the terms of the agreement, Janssen gains exclusive worldwide rights to develop and
commercialize ASP015K, except in Japan, as an oral treatment for immune-mediated inflammatory
diseases. In addition to an upfront payment, Janssen and Astellas have agreed to future milestone and
royalty payments if certain development and commercialization milestones are achieved. Astellas will be
responsible for completing the ongoing Phase 2b studies. Janssen will be responsible for all other
development, clinical and regulatory filing activities in its territories. Astellas will continue development
and commercialization of ASP015K in Japan.
ASP105K is an oral, small molecule Janus Kinase (JAK) inhibitor, which blocks critical components of
signaling mechanisms used by a number of inflammatory cytokines, including those that are believed to be
important to mediating disease in people with immune-mediated inflammatory diseases. ASP015K is
currently in Phase 2b studies evaluating the efficacy and safety of once-daily oral dosing in the treatment
of moderate-to-severe RA. A Phase 2a study in the treatment of moderate-to-severe plaque psoriasis has
About the Janssen Pharmaceutical Companies of Johnson & Johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving
the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and
prostate cancer), immunology (e.g., RA, inflammatory bowel disease (IBD) and psoriasis), neuroscience
(e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis),
and cardiovascular and metabolic diseases (e.g., diabetes).
Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working
side-by-side with healthcare stakeholders, based on partnerships of trust and transparency.
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Biotech, Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; impact of business combinations; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies; and disruptions due to natural disasters. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at Johnson & Johnson. Neither Janssen Biotech, Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.
Technical Information Table 1 lists over 450 chemicals whose corrosive Tefzel ® fluoropolymer resin is a proven performer incharacteristics create problems which can often bethe chemical and petrochemical processing indus-solved by specifying Tefzel ® fluoropolymer. Thetries. It has gained notable recognition for its uniquemaximum use temperature for each chemicalproperties and des
Fiche stratégique Paludisme 2009 – 2011 Avec le VIH/sida et la tuberculose, le paludisme est l’un des principaux problèmes de santé publique menaçant le développement des pays les plus pauvres. Paludisme et pauvreté sont liés et les populations rurales sont particulièrement touchées. De plus, la co-infection VIH-paludisme, deux maladies dépendantes de l’immunité cellula